Background and study aims: Although trials evaluating the preventive effect of glyceryl trinitrate (GTN; nitroglycerin) on pancreatitis occurring after endoscopic retrograde cholangiopancreatography (ERCP) have been reported, there is no agreement as to whether prophylactic GTN treatment can in fact reduce the incidence of post-ERCP pancreatitis. We performed a meta-analysis to compare the effects of prophylactic GTN with placebo on post-ERCP pancreatitis.
Study design: Databases including PubMed, EMBASE, the Cochrane Library, and the Science Citation Index were searched to find relevant randomized controlled trials (RCTs). Two reviewers independently identified relevant trials evaluating the prophylactic effect of GTN on the occurrence of post-ERCP pancreatitis. The outcome measure was the incidence of post-ERCP pancreatitis.
Results: Eight trials involving 1920 patients were analyzed. Meta-analysis showed that the incidence of post-ERCP pancreatitis was significantly reduced by GTN treatment (GTN group 5.9 %, placebo group 9.8 %, P = 0.002), with a relative risk of 0.61 (95 % confidence interval 0.44 – 0.84). Patients who received GTN were 39 % less likely to develop pancreatitis. Subgroup analyses suggested that GTN administered by the sublingual or transdermal route may be useful.
Conclusions: Prophylactic GTN is useful for prevention of post-ERCP pancreatitis, but the optimal dosage and the optimal route and timing of administration need further clarification before this treatment can come into routine clinical use.
References
1
Tsujino T, Isayama H, Komatsu Y. et al .
Risk factors for pancreatitis in patients with common bile duct stones managed by endoscopic papillary balloon dilation.
Am J Gastroenterol.
2005;
100
38-42
2
Masci E, Toti G, Mariani A. et al .
Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.
Am J Gastroenterol.
2001;
96
417-423
3
Loperfido S, Angelini G, Benedetti G. et al .
Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study.
Gastrointest Endosc.
1998;
48
1-10
4
Freeman M L, DiSario J A, Nelson D B. et al .
Risk factors for post-ERCP pancreatitis: a prospective, multicenter study.
Gastrointest Endosc.
2001;
54
425-434
5
Andriulli A, Loperfido S, Napolitano G. et al .
Incidence rates of post-ERCP complications: a systematic survey of prospective studies.
Am J Gastroenterol.
2007;
102
1781-1788
6
Andriulli A, Leandro G, Federici T. et al .
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Gastrointest Endosc..
2007;
65
624-632
7
Bai Y, Gao J, Zou D W. et al .
Prophylactic octreotide administration does not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Pancreas.
2008;
37
241-246
8
Bai Y, Gao J, Shi X. et al .
Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Pancreatology.
2008;
8
504-509
9
Bai Y, Gao J, Zhang W. et al .
Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis.
Aliment Pharmacol Ther.
2008;
28
557-564
10
Elmunzer B J, Waljee A K, Elta G H. et al .
A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis.
Gut.
2008;
57
1262-1267
11
Marsh N, Marsh A.
A short history of nitroglycerine and nitric oxide in pharmacology and physiology.
Clin Exp Pharmacol Physiol.
2000;
27
313-319
12
Staritz M, Poralla T, Ewe K. et al .
Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure.
Gut.
1985;
26
194-197
13
Brandstätter G, Schinzel S, Wurzer H.
Influence of spasmolytic analgesics on motility of sphincter of Oddi.
Dig Dis Sci.
1996;
41
1814-1818
14
Staritz M, Poralla T, Dormeyer H H. et al .
Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation.
Gastroenterology.
1985;
88
1807-1811
15
Uchida N, Ezaki T, Hirabayashi S. et al .
Endoscopic lithotomy of common bile duct stones with sublingual nitroglycerin and guidewire.
Am J Gastroenterol.
1997;
92
1440-1443
16
Wehrmann T, Schmitt T, Stergiou N. et al .
Topical application of nitrates onto the papilla of Vater: manometric and clinical results.
Endoscopy.
2001;
33
323-328
17
Sudhindran S, Bromwich E, Edwards P R.
Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis.
Br J Surg.
2001;
88
1178-1182
18
Moretó M, Zaballa M, Casado I. et al .
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial.
Gastrointest Endosc.
2003;
57
1-7
19
Kaffes A J, Bourke M J, Ding S. et al .
A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
Gastrointest Endosc.
2006;
64
351-357
20
Schulz K F, Chalmers I, Hayes R J. et al .
Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
JAMA.
1995;
273
408-412
21
Moher D, Pham B, Jones A. et al .
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?.
Lancet.
1998;
352
609-613
22 Higgins J PT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK; John Wiley & Sons, Ltd 2005
23
Bai Y, Gao J, Zou D W. et al .
Prophylactic antibiotics can not reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials.
Am J Gastroenterol.
2008;
103
104-110
24
DerSimonian R, Laird N.
Meta-analysis in clinical trials.
Control Clin Trials.
1986;
7
177-188
25
Berlin J A, Laird N M, Sacks H S. et al .
A comparison of statistical methods for combining event rates from clinical trials.
Stat Med.
1989;
8
141-151
26
Higgins J P, Thompson S G.
Quantifying heterogeneity in a metaanalysis.
Stat Med.
2002;
21
1539-1558
27
Egger M, Davey Smith G, Schneider M. et al .
Bias in metaanalysis detected by a simple, graphical test.
BMJ.
1997;
315
629-634
28
Luman W, Pryde A, Heading R C. et al .
Topical glyceryl trinitrate relaxes the sphincter of Oddi.
Gut.
1997;
40
541-543
29
Ghori A, Hallisey M, Nwokolo C. et al .
The secret (GTN) of successful ERCP cannulation: a prospective randomised controlled study.
J R Coll Surg Edinb.
2002;
47
634-647
30
Murray M A, Kaffes A J, Kwan V. et al .
A prospective randomised double blind placebo controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis-final results.
J Gastroenterol Hepatol.
2003;
18 (Suppl)
B46
31
Moretó M, Zaballa M, Ramírez K. et al .
Transdermal glyceryl trinitrate in the prevention of post-ERCP pancreatitis.
Gastrointest Endosc.
2000;
51
AB67
32
Talwar A, Dare C, Pain J.
Does topical GTN on the sphincter of Oddi facilitate ERCP? A double-blind randomized control trial.
Surg Endosc.
2005;
19
902-904
33
Nøjgaard C, Hornum M, Elkjaer M. et al .
Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled multicenter trial.
Gastrointest Endosc.
2009;
69
e31-e37
34
Beauchant M, Ingrand P, Favriel J M. et al .
Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial.
Endoscopy.
2008;
40
631-636
35
Hao J Y, Wu D F, Wang Y Z. et al .
Prophylactic effect of glyceryl trinitrate on post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized placebo-controlled trial.
World J Gastroenterol.
2009;
15
366-368
36
Cotton P B, Lehman G A, Vennes J. et al .
Endoscopic sphincterotomy complications and their management. An attempt at consensus.
Gastrointest Endosc.
1991;
37
383-393
37
Moretó M, Zaballa M.
Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis.
Br J Surg.
2002;
89
628-author reply 629
38 Altman D G. How large a sample? . In: Gore SM, Altman DG, eds Statistics in practice. London; British Medical Association 1982
39
Normand S L.
Meta-analysis: formulating, evaluating, combining, and reporting.
Stat Med.
1999;
18
321-359
40
Berlin J A, Santanna J, Schmid C H. et al .
Individual patient- versus group-level data meta-regressions for the investigation of treatment effects modifiers: ecological bias rears its ugly head.
Stat Med.
2002;
21
371-387
41
Ioannidis J P, Patsopoulos N A, Rothstein H R.
Reasons or excuses for avoiding meta-analysis in forest plots.
BMJ.
2008;
336
1413-1415
42 McGovern D PB, Valori R M, Summerskill W SM. et al .Key topics in evidence-based medicine. Oxford; BIOS 2001
43
Shao L M, Chen Q Y, Chen M Y, Cai J T.
Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis.
Dig Dis Sci.
2009;
Jan 22 (epub ahead of print)
44 Gilman A G, Goodman L S, Gilman A. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York; Macmillan 1985
45
Birkett D J.
Pharmacokinetics made easy: 5: Bioavailability and first pass clearance.
Australian Prescriber.
1991;
14
14-16
46
Testoni P A.
Pharmacological prevention of post-ERCP pancreatitis: the facts and the fiction.
JOP.
2004;
5
171-178
1 Note: Dr. Bai Yu and Dr. Xu Can are co-first authors.
Z.-S. LiMD
Department of Gastroenterology Changhai Hospital Second Military Medical University
168 Changhai Road Shanghai China
Fax: +86-21-55621735
eMail: li.zhaoshen@hotmail.com